Page last updated: 2024-12-05

anthrarobin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Anthrarobin is a synthetic compound derived from chrysarobin, a natural product found in the wood of the Araroba tree. It is used topically as an anti-inflammatory and anti-psoriatic agent. Its mechanism of action is believed to involve the inhibition of DNA synthesis and cell proliferation. Anthrarobin is often used to treat psoriasis, eczema, and other inflammatory skin conditions. It is also being studied for its potential in treating certain types of cancer. Anthrarobin is a potent irritant and can cause skin irritation and discoloration. It should be used with caution and only under the supervision of a healthcare professional.'

anthrarobin: antipsoriatic; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anthrarobin : An anthracenetriol having the three hydroxy substituents at the 1-, 2- and 10-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11342
CHEMBL ID144924
CHEBI ID37504
SCHEMBL ID187228
MeSH IDM0100573

Synonyms (39)

Synonym
BIDD:GT0631
brn 3531675
desoxyalizarin
leukoalizarin
ccris 5596
einecs 209-410-6
leucoalizarin
nsc 60015
anthracene-1,2,10-triol
1,2,10-trihydroxyanthracene
CHEBI:37504 ,
3,4,9-trihydroxyanthracene
3,4-dihydroxyanthranol
1,2,10-anthratriol
1,10-anthracenetriol
1,10-anthratriol
anthrarobin
3,9,-trihydroxyanthracene
nsc-60015
nsc60015
577-33-3
anthrarobin, technical grade, 85%
CHEMBL144924
e0t985y674 ,
unii-e0t985y674
4-06-00-07601 (beilstein handbook reference)
FT-0622424
anthrarobin [mi]
1,2,10-anthracenetriol
SCHEMBL187228
TZIQWQARHPGHIG-UHFFFAOYSA-N
3,4-dihydroxyanthrol
3,4,9,-trihydroxyanthracene
DTXSID20206401
Q27117172
nsc60015;leucoalizarin
CS-0064369
HY-114812
AKOS040746575
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
anthracenetriolA polyphenol that is anthracene carrying three hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID80631Percent relaxation of isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID641626Inhibition of Mycobacterium tuberculosis RmlD assessed as inhibition of dTDP-beta-6-deoxy-L-lyxo-4-hexulose to dTDP-beta-L-rhamnose conversion at 10 ug/ml2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) identified by virtual screening.
AID80624Percent relaxation using isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (57.14)18.7374
1990's2 (28.57)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.77 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]